Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host

Journal of Leukocyte Biology

Volumn 72, Issue 5, 2002, Pages 898-912

  Hummel, Susanne ^a   Wilms, Daniela ^a   Vitacolonna, Mario ^a   Zöller, Margot ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

Carcinoma; Graft versus host disease; Rodent; Transplantation

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLONY FORMATION; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; LYMPHOCYTE DEPLETION; LYMPHOPOIESIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE; THYMUS; TUMOR GROWTH;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL DIVISION; GRAFT VS HOST REACTION; HOST VS GRAFT REACTION; KILLER CELLS, NATURAL; KINETICS; LYMPHOCYTE DEPLETION; LYMPHOPOIESIS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOPOIESIS; NEOPLASMS, EXPERIMENTAL; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA; RODENTIA;

EID: 0036851892     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. vanBesien, K., Keralavarma, B., Devine, S., Stock, W. (2001) Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia 15, 1317-1325.
2. Cutler, C., Giri, S., Jeyapalan, S., Paniagua, D., Viswanathan, A., Antin, J. H. (2001) Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: A meta-analysis. J. Clin. Oncol. 19, 3685-3691.
3. Cutler, C., Antin, J. H. (2001) Peripheral blood stem cells for allogeneic transplantation: A review. Stem Cells 19, 108-117.
4. Schimmer, A. D., Jamal, S., Messner, H., Keating, A., Meharchand, J., Huebsch, L., Walker, I., Benger, A., Gluck, S., Smith, A. (2000) Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network Canada. Bone Marrow Transplant. 26, 859-864.
5. Matthes-Martin, S, Mann, G., Peters, C., Lion, T., Fritsch, G., Haas, O. A., Potschger, U., Gadner, H. (2000) Allogeneic bone marrow transplantation for juvenile myelomonocytic leukaemia: A single centre experience and review of the literature. Bone Marrow Transplant. 26, 377-382.
6. Porter, D. L., Antin, J. H. (1999) The graft-versus-leukemia effects of allogeneic cell therapy. Annu. Rev. Med. 50, 369-386.
7. Rubin, C. M., Mick, R., Johnson, F. L. (1996) Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: Toxicity and outcome. Bone Marrow Transplant. 18, 533-540.
8. Ferrara, J. L. (2000) Pathogenesis of acute graft-versus-host disease: Cytokines and cellular effectors. J. Hematother. Stem Cell Res. 9, 299-306.
9. Vindelov, L. (2001) Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT). Eur. J. Haematol. 66, 73-82.
10. Dansey, R. D. Baynes, R. D. (2001) Nonablative allogeneic hematopoietic stem cell transplantation. Curr. Opin. Oncol. 13, 27-32.
11. Slavin, S., Nagler, A., Aker, M., Shapira, M. Y., Cividalli, G., Or, R. (2001) Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders. Rev. Clin. Exp. Hematol. 5, 135-146.
12. Feinstein, L., Storb, R. (2001) Nonmyeloablative hematopoietic cell transplantation. Curr. Opin. Oncol. 13, 95-100.
13. Carella, A. M., Champlin, R., Slavin, S., McSweeney, P., Storb, R. (2000) Mini-allografts: Ongoing trials in humans. Bone Marrow Transplant. 25, 345-350.
14. Sandmaier, B. M., McSweeney, P., Yu, C., Storb, R. (2000) Nonmyeloablative transplants: Preclinical and clinical results. Semin. Oncol. 27, 78-81.
15. Maris, M., Woolfrey, A., McSweeney, P. A. (2001) Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21st century. Front. Biosci. 6, G13-G16.
16. Taniguchi, H., Abe, M., Shirai, T., Fukao, K., Nakauchi, H. (1995) Reconstitution ratio is critical for alloreactive T cell deletion and skin graft survival in mixed bone marrow chimeras. J. Immunol. 155, 5631-5636.
17. Bomhauser, M., Thiede, C., Platzbecker, U., Jenke, A., Helwig, A., Plettig, R., Freiberg-Richter, J., Rollig, C., Geissler, G., Lutterbeck, K., Oelschlagel, U., Ehninger, G. (2001) Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin. Cancer Res. 7, 2254-2262.
18. Lan, F., Zeng, D., Higuchi, M., Huie, P., Higgins, J. P., Strober, S. (2001) Predominance of NK1.1(+)TCRalphabeta(+) or DX5(+)TCRalphabeta(+) T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "Natural suppressor" cells. J. Immunol. 167, 2087-2096.
19. Horwitz, M. E., Barrett, A. J., Brown, M. R., Carter, C. S., Childs, R., Gallin, J. I., Holland, S. M., Linton, G. F., Miller, J. A., Leitman, S. F., et al. (2001) Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N. Engl. J. Med. 344, 881-888.
20. Spitzer, T. R. (2000) Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist 5, 215-223.
21. Childs, R. W., Clave, E., Tisdale, J., Plante, M., Hensel, N., Barrett, J. (1999) Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect. J. Clin. Oncol. 17, 2044-2049.
22. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., et al. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91, 756-763.
23. Prigozhina, T. B., Gurevitch, O., Zhu, J., Slavin, S. (1997) Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic tissues: I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specific host lymphocytes. Transplantation 63, 1394-1399.
24. Juckett, M., Rowlings, P., Hessner, M., Keever-Taylor, C., Burns, W., Camitta, B., Casper, J., Drobyski, W. R., Hanson, G., Horowitz, M., et al. (1998) T cell-depleted allogeneic bone marrow transplantation for highrisk non-Hodgkin's lymphoma: Clinical and molecular follow-up. Bone Marrow Transplant. 21, 893-899.
25. Drobyski, W. R. (2000) Evolving strategies to address adverse transplant outcomes associated with T cell depletion. J. Hematother. Stem Cell Res. 9, 327-337.
26. Mencacci, A., Perruccio, K., Bacci, A., Cenci, E., Benedetti, R., Martelli, M. F., Bistoni, F., Coffman, R., Velardi, A., Romani, L. (20001) Defective antifungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell-depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists. Blood 97, 1483-1490.
27. Reisner, Y., Bachar-Lustig, E., Li, H. W., Aversa, F., Velardi, A., Martelli, M. F. (1999) The role of megadose CD34+ progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation Ann. N. Y. Acad. Sci. 872, 336-350.
28. Martin, P. J., Rowley, S. D., Anasetti, C., Chauncey, T. R., Gooley, T., Petersdorf, E. W., van-Burik, J. A., Flowers, M. E., Storb, R., Appelbaum, F. R., et al. (1999) A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood 94, 2192-2199.
29. Garderet, L., Snell, V., Przepiorka, D., Schenk, T., Lu, J. G., Marini, F., Gluckman, E., Andreeff M., Champlin, R. E. (1999) Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation 67, 124-130.
30. Barsoukov, A. A., Moore, P. F., Storb, R., Santos, E. B., Sandmaier, B. M. (1999) The use of an anti-TCRalphabeta monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. Transplantation 67, 1329-1335.
31. Storb, R., Yu, C., Zaucha, J. M., Deeg, H. J., Georges, G., Kiem, H. P., Nash, R. A., McSweeney, P. A., Wagner, J. L. (1999) Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 94, 2523-2529.
32. Blazar, B. R., Taylor, P. A., Panoskaltsis-Mortari, A., Buhlman, J., Xu, J., Flavell, R. A., Korngold, R., Noelle, R., Vallera, D. A. (1997) A blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated allore-activity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J. Immunol. 158, 29-39.
33. Koch, U., Korngold, R. (1997) A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers. Blood 89, 2880-2890.
34. Blazar, B. R., Korngold, R., Vallera, D. (1997) Recent advances in graft-versus-host disease (GVHD) prevention. Immunol. Rev. 157, 79-109.
35. Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., Velardi, A. (1999) A role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94, 333-339.
36. Nikolic, B., Cooke, D. T., Zhao, G., Sykes, M. (2001) Both gamma delta T cells and NK cells inhibit the engraftment of xenogeneic rat bone marrow cells and the induction of xenograft tolerance in mice, J. Immunol. 166, 1398-1404.
37. Kawai, T., Wee, S. L., Bazin, H., Latinne, D., Phelan, J., Boskovic, S., Ko, D. S., Hong, H. Z., Mauiyyedi, S., Nadazdin, O., et al. (2000) Association of natural killer cell depletion with induction of mixed chimerism and allograft tolerance in non-human primates. Transplantation 70, 368-374.
38. Lee, L. A., Sergio, J. J., Sykes, M. (1996) Natural killer cells weakly resist engraftment of allogeneic long-term multilineage-repopulating hematopoietic stem cells. Transplantation 61, 125-132.
39. Kumar, V., George, T., Yu, Y. Y., Liu, J., Bennett, M. (1997) Role of murine NK cells and their receptors in hybrid resistance. Curr. Opin. Immunol. 9, 52-56.
40. Lanier, L. L. (1998) Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell 92, 705-707.
41. Long, E. O., Burshtyn, D. N., Clark, W. P., Peruzzi, M., Rajagopalan, S., Rojo, S., Wagtmann, N., Winter, C. C. (1997) Killer cell inhibitory receptors: Diversity, specificity, and function. Immunol. Rev. 155, 135-144.
42. Vales-Gomez, M., Reyburn, H., Strominger, J. (2000) Interaction between the human NK receptors and their ligands. Crit. Rev. Immunol. 20, 223-244.
43. Khakoo, S. I., Rajalingam, R., Shum, B. P., Weidenbach, K., Flodin, L., Muir, D. G., Canavez, F., Cooper, S. L., Valiante, N. M., Lanier, L. L., et al. (2000) Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans. Immunity 12, 687-698.
44. Brooks, A. G., Boyington, J. C., Sun, P. D. (2000) Natural killer cell recognition of HLA class I molecules. Rev. Immunogenet. 2, 433-448.
45. Rajagopalan, S., Long, E. O. (1999) A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 189, 1093-1100.
46. Kim, J., Chwae, Y. J., Kim, M. Y., Choi, I. H., Park, J. H., Kim, S. J. (1997) Molecular basis of HLA-C recognition by p58 natural killer cell inhibitory receptors. J. Immunol. 159, 3875-3882.
47. Cambiaggi, A., Verthuy, C., Naquet, P., Romagne, F., Ferrier, P., Biassoni, R., Moretta, A., Moretta, L., Vivier, E. (1997) Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor. Proc. Natl. Acad. Sci. USA 94, 8088-8092.
48. Lanier, L. L. (2001) Face off - The interplay between activating and inhibitory immune receptors. Curr. Opin. Immunol. 13, 326-331.
49. Campbell, K. S., Cella, M., Carretero, M., Lopez-Botet, M., Colonna, M. (1998) Signaling through human killer cell activating receptors triggers tyrosine phosphorylation of an associated protein complex. Eur. J. Immunol. 28, 599-609.
50. Christensen, M. D., Geisler, C. (2000) Recruitment of SHP-1 protein tyrosine phosphatase and signalling by a chimeric T-cell receptor-killer inhibitory receptor. Scand. J. Immunol. 51, 557-564.
51. Bruhns, P., Marchetti, P., Fridman, W. H., Vivier, E., Daeron, M. (1999) Differential roles of N- and C-terminal immunoreceptor tyrosine-based inhibition motifs during inhibition of cell activation by killer cell inhibitory receptors. J. Immunol. 162, 3168-3175.
52. Burshtyn, D. N., Shin, J., Stebbins, C., Long, E. O. (2000) Adhesion to target cells is disrupted by the killer cell inhibitory receptor. Curr. Biol. 10, 777-780.
53. Ortaldo, J. R., Winkler-Pickett, R., Willette-Brown, J., Wange, R. L., Anderson, S. K., Palumbo, G. J., Mason, L. H., McVicar, D. W. (1999) Structure/function relationship of activating Ly-49D and inhibitory Ly-49G2 NK receptors. J. Immunol. 163, 5269-5277.
54. Albi, N., Ruggeri, L., Aversa, F., Merigiola, C., Tosti, A., Tognellini, R., Grossi, C. E., Martelli, M. F., Velardi, A. (1996) Natural killer (NK)-cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after "three-loci" HLA-incompatible bone marrow transplantation. Blood 87, 3993-4000.
55. Huard, B., Karlsson, L. (2000) KIR expression on self-reactive CD8+ T cells is controlled by T-cell receptor engagement. Nature 403, 325-328.
56. Huard, B., Karlsson, L. (2000) A subpopulation of CD8+ T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: Evidence for a role of KIR in the control of peripheral tolerance. Eur. J. Immunol. 30, 1665-1675.
57. Uhrberg, M., Valiante, N. M., Young, N. T., Lanier, L. L., Phillips, J. H., Parham, P. (2001) The repertoire of killer cell Ig-like receptor and CD94:NKG2A receptors in T cells: Clones sharing identical alpha beta TCR rearrangement express highly diverse killer cell Ig-like receptor patterns. J. Immunol. 166, 3923-3932.
58. Vely, F., Peyrat, M., Couedel, C., Morcet, J., Halary, F., Davodeau, F., Romagne, F., Scotet, E., Saulquin, X., Houssaint, E., et al. (2001) Regulation of inhibitory and activating killer-cell Ig-like receptor expression occurs in T cells after termination of TCR rearrangements. J. Immunol. 166, 2487-2494.
59. Yamada, N., Nagatani, T., Takiguchi, M. (1998) T cells expressing killer cell inhibitory receptors do not carry TCR for alloantigens. Hum. Immunol. 59, 488-492.
60. Pende, D., Accame, L., Pareti, L., Mazzocchi, A., Moretta, A., Parmiani, G., Moretta, L. (1998) The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur. J. Immunol. 28, 2384-2394.
61. Morecki, S., Moshel, Y., Gelfend, Y., Pugatsch, T., Slavin, S. (1997) Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma. Int. J. Cancer 71, 59-63.
62. Pelot, M. R., Pearson, D. A., Swenson, K., Zhao, G., Sachs, J., Yang, Y. G., Sykes, M. (1999) Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol. Blood Marrow Transplant. 5, 133-143.
63. Lowdell, M. W., Lamb, L., Hoyle, C., Velardi, A., Prentice, H. G. (2001) Non-MHC-restricted cytotoxic cells: Their roles in the control and treatment of leukaemias. Br. J. Haematol. 114, 11-24.
64. Dolstra, H., Fredrix, H., van der Meer, A., de Witte, T., Figdor, C., van de Wiel van Kemenade, E. (2001) TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplant. 27, 1087-1093.
65. Morecki, S., Gelfand, Y., Nagler, A. (2001) Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs. myeloablative regimen. Bone Marrow Transplant. 28, 243-249.
66. Teshima, T., Mach, N., Hill, G. R., Pan, L., Gillessen, S., Dranoff, G., Ferrara, J. L. (2001) Tumor cell vaccine elicits potent antitumor immunity after allogeneic T cell-depleted bone marrow transplantation. Cancer Res. 61, 162-171.
67. Bakker, A. B., Phillips, J. H., Figdor, C. G., Lanier, L. L. (1998) Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J. Immunol. 160, 5239-5245.
68. Murphy, G. P., Hrushesky, W. J. (1973) A murine renal cell carcinoma, J. Natl. Cancer Inst. 50, 1013-1025.
69. Koch, N., Hämmerling, G. J., Tada, N., Kimura, S., Hämmerling, U. (1982) Cross-blocking studies with monoclonal antibodies against I-A molecules of haplotypes b, d and k. Eur. J. Immunol. 12, 909-914.
70. Wysocki, L. J., Sato, V. L. (1978) Panning for lymphocytes: A method for cell selection. Proc. Natl. Acad. Sci. USA 75, 2844-2848.
71. Cattoretti, G., Berti, E., Schiró, R., D'Amato, L., Valeggio, C., Rilke, F, (1988) Improved avidin-biotin-peroxidase complex (ABC) staining. Histochem. J. 20, 75-80.
72. Testa, N. G., Molineux, G. (eds) (1993) Haemopoiesis: A Practical Approach, Oxford, UK, Oxford University Press.
73. Winkler, T. H., Melchers, F., Rolink, A. G. (1995) Interleukin-3 and interleukin-7 are alternative growth factors for the same B-cell precursors in the mouse. Blood 85, 2045-2051.
74. Lefkovits, I., Waldmann, H. (eds) (1978) Limiting Dilution Analysis of Cells in the Immune System, Cambridge, UK, Cambridge University Press.
75. Matzinger, P. (1991) The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145, 185-192.
76. Banat, A., Christ, O., Cochlovius, B., Pralle, H. B., Zöller, M. (2001) Tumor induced deviation of immune response and its correction. Cancer Immunol. Immunother. 49, 573-586.
77. Murphy, W. J., Longo, D. L. (1997) The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Immunol. Rev. 157, 167-176.
78. Shenoy, S., Mohanakumar, T., Todd, G., Westhoff, W., Dunnigan, K., Adkins, D. R., Brown, R. A., DiPersio, J. F. (1999) Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant. 23, 335-346.
79. Nakamura, H., Komatsu, K., Ayaki, M., Kawamoto, S., Murakami, M., Uoshima, N., Yagi, T., Hasegawa, T., Yasumi, M., Karasuno, T., et al. (2000) Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFNgamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Allergy Clin. Immunol. 106, S45-S50.
80. Imoto, S., Oomoto, Y., Murata, K., Das, H., Murayama, T., Kajimoto, K., Sugimoto, T., Gomyo, H., Nakagawa, T., Nishimura, R., et al. (2000) Kinetics of serum cytokines after allogeneic bone marrow transplantation: Interleukin-5 as a potential marker of acute graft-versus-host disease. Int. J. Hematol. 72, 92-97.
81. Martin, P. J. (1995) Influence of alloreactive T cells on initial hematopoietic reconstitution after marrow transplantation. Exp. Hematol. 23, 174-179.
82. Barge, R. M., Brouwer, R. E., Beersma, M. F., Starrenburg, C. W., Zwinderman, A. H., Hale, G., Waldmann, H., den-Ottolander, G. J., Falkenburg, J. H., Willemze, R., et al. (2001) Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: Effect of stem cell source on short- and long-term outcome. Bone Marrow Transplant. 27, 1053-1058.
83. Mattsson, J., Uzunel, M., Remberger, M., Tammik, L., Omazic, B., Levitsky, V., Zou, J. Z., Hentschke, P., Ringden, O. (2001) Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation. Clin. Exp. Immunol. 123, 162-169.
84. Fehse, B., Goldmann, M., Frerk, O., Bulduk, M., Zander, A. R. (2000) Depletion of alloreactive donor T cells using immunomagnetic cell selection. Bone Marrow Transplant. 26, S39-S42.
85. Verfuerth, S., Peggs, K., Vyas, P., Barnett, L., O'Reilly, R. J., Mackinnon, S. (2000) Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. Blood 95, 3990-3905.
86. Yu, X. Z., Bidwell, S. J., Martin, P. J., Anasetti, C. (2001) Anti-CD3 epsilon F(ab′)2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens. J. Immunol. 166, 5835-5839.
87. Blazar, B. R., Lees, C. J., Martin, P. J., Noelle, R. J., Kwon, B., Murphy, W., Taylor, P. A. (2000) Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J. Immunol. 165, 4901-4909.